Co-Founder
CurrentSilicon Valley startup, Level 42 AI, Inc’s software-defined hardware captures and synchronizes traditionally discarded or unobserved multi-modal data streams to predict and quantify health state, from short 5-to-30 second data snippets.Level 42 AI, Inc is conducting clinical studies to discover and validate COVID-19 biosignatures with Johns Hopkins School of Medicine (JHM) and University of California-San Francisco (UCSF). Level 42 AI, Inc’s COVID-19 biosignature is an AI algorithm that deploys state-of-the-art, proprietary domain-adaptable machine learning techniques to elucidate and differentiate early cellular and tissue mechano-transduction changes and the body's immune response to SARS-CoV-2 infection.Without the right algorithms to extract actionable insight, the real value of high-resolution sensor data fusion will remain hidden. Popular approaches such as Deep Learning model correlation, not causal relationships, and do not support extrapolation from the data. In contrast, Level 42 AI, Inc’s novel Structural Machine Learning (SML) platform, is a natural feedforward and feedback platform, where data causal relationships, exploration and exploitation can be achieved faster and more accurately to differentiate and learn across diseases.